Form 8-K - Current report:
SEC Accession No. 0001171843-24-005515
Filing Date
2024-10-04
Accepted
2024-10-04 16:55:20
Documents
18
Period of Report
2024-10-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_100424.htm   iXBRL 8-K 28077
2 EXHIBIT 1.1 exh_11.htm EX-1.1 221249
3 EXHIBIT 5.1 exh_51.htm EX-5.1 14282
7 GRAPHIC faskenheader.jpg GRAPHIC 19375
8 GRAPHIC faskenfooter.jpg GRAPHIC 1030
9 GRAPHIC faskenlogo.jpg GRAPHIC 2956
  Complete submission text file 0001171843-24-005515.txt   529122

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE edsa-20241003_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE edsa-20241003_pre.xml EX-101.PRE 22367
6 XBRL SCHEMA FILE edsa-20241003.xsd EX-101.SCH 3027
21 EXTRACTED XBRL INSTANCE DOCUMENT f8k_100424_htm.xml XML 3503
Mailing Address 100 SPY COURT MARKHAM A6 L3R 5H6
Business Address 100 SPY COURT MARKHAM A6 L3R 5H6 (905) 475-1234
Edesa Biotech, Inc. (Filer) CIK: 0001540159 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37619 | Film No.: 241355470
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)